Trial Profile
A Prospective, Active-controlled, Randomized, Double blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab of Enzene Biosciences Limited versus Innovator Denosumab in the Treatment of Postmenopausal Osteoporosis
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Jan 2020
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Postmenopausal osteoporosis
- Focus Adverse reactions; Therapeutic Use
- Sponsors Alkem Laboratories; Enzene Biosciences
- 10 Jan 2020 Status changed from recruiting to active, no longer recruiting.
- 13 Nov 2018 New trial record
- 12 Nov 2018 Status changed from not yet recruiting to recruiting.